ALX Oncology Holdings Inc. (ALXO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 01:56PM EDT. Market open.
| Previous Close | 15.00 |
| Open | 15.00 |
| Bid | 14.39 x 100 |
| Ask | 14.47 x 100 |
| Day's Range | 14.08 - 15.35 |
| 52 Week Range | 3.94 - 17.83 |
| Volume | |
| Avg. Volume | 538,656 |
| Market Cap | 751.544M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
- GuruFocus.com
Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares
Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), sold 12,000 shares of the company on May 13, 2024.
- Zacks
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
© 2024 Yahoo. All rights reserved.